Express . . . Preclinical results of anti-PD-1 therapy resistance and regenerative metaCD28 bispecific antibodies were published.

Today, regeneron announced that its new bispecific antibody targeting CD28 costimulatory receptor, combined with anti PD-1 antibody, can overcome the resistance of anti PD-1 monotherapy in a variety of preclinical cancer models, and trigger the long-term memory of T cells for tumor.
the research on this innovative bispecific antibody was published as a cover article in the latest issue of Science Translational Medicine.
the decision of regenerant to develop a new type of CD28 bispecific antibody is based on the understanding of the ability of T cells to kill cancer.
T cells must receive at least two different stimuli to be fully activated to kill tumor cells.
when T cells "recognize" specific proteins on cancer cells through the T cell receptor / CD3 complex, they receive the first stimulus signal.
this enables T cells to produce the best response to the second "co stimulation" signal, while the interaction between CD28 costimulatory receptor and antigen presenting cell on T cell produces the strongest "co stimulation" signal.
CD28 costimulatory bispecific antibody of regenerator binds to specific antigen on cancer cell surface at one end and CD28 receptor on T cell surface at the other end.
it synergistically enhances anti-PD-1 therapy and / or anti-tumor activity of CD3 bispecific molecules by selectively activating the CD28 pathway of T cells in tumor site.
previously, the company published a cover article on Science Translational Medicine in January this year, introducing the benefits of combining CD28 and CD3 bispecific receptors in the treatment of prostate and ovarian cancer.
in the latest scientific papers, researchers found that the combination of CD28 bispecific antibody and anti PD-1 antibody libtayo in the treatment of prostate cancer or other epithelial cancer can synergistically increase the tumor killing effect of T cells in animal models and cell culture models.
most importantly, the combination overcomes the resistance of two cancers to PD-1 monotherapy.
in addition, T cells acquired long-term memory of cancer after treatment, and showed anti-cancer activity when the treated mice were re implanted into the tumor.
when libtayo is administered alone, this long-term T-cell immune memory response is limited.
"preclinical studies have shown that our new CD28 bispecific antibody, when used in combination with other immunotherapies, triggers a targeted tumor killing effect in cancers that are generally resistant to current monotherapy regimens," said Dimitris, senior director of cancer immunology research at regenerant "In addition, we have not observed systemic cytokine release syndrome in animal studies," Dr. skokos said.
historically, systemic cytokine release has been a challenge for CD28 super agonists.
"this year, regenerant plans to carry out clinical trials to test three different dual specific CD28 candidates.
the first costimulatory bispecific antibody clinical trial of Regent is currently under way to evaluate the safety and efficacy of psmaxcd28 (regn5678) combined with libtayo in the treatment of prostate cancer.
by the end of the year, the company plans to start a clinical trial of egfrxcd28 (regn7075) combined with libtayo in patients with solid tumors.
these patients may include non-small cell lung cancer, head and neck squamous cell carcinoma, skin squamous cell carcinoma and colorectal cancer.
another clinical trial will study muc16xcd28 (regn5668) combined with libtayo or muc16xcd3 (regn4018) in the treatment of ovarian cancer.


< PD-1immunotherapy. Science Translational Medicine, DOI: 10.1126/ scitranslmed.aba2325 Note: the purpose of this article is to introduce the progress of medical and health research, not to recommend treatment options.
if you need guidance on treatment plan, please go to a regular hospital.